Improving access to clinical trial participation among underrepresented kidney cancer patients
Abstract
430
Background:
It is well-studied that multiple barriers exist to oncology clinical trial participation. Patient (pt)-related barriers include lack of education about clinical trials and increased financial burden. Literature is saturated with studies identifying barriers to oncology trial enrollment, but limited randomized studies exist addressing possible solutions. Our study addresses this educational gap, with an overall goal of increasing access to clinical trial participation.
Methods:
A clinical trial education program targeting kidney cancer patients was developed. By partnering with kidney cancer pts (N = 8) and using semi-structured interviews, information about their clinical trial knowledge was gathered. An in-person educational program and animated video covering varied topics pertaining to clinical trials were created. Pre/post program surveys captured participant demographics and current knowledge/perceptions about clinical trials. Wilcoxon signed-ranked test was used to compare the pre/post responses.
Results:
To date, 77 pts completed both surveys. Demographics included: Male (73.7%), Female (26.3%), < 60 years (23.7%), ≥ 60 years (76.3%), White (89.6%), Black (3.9%), American Indian (1.3%), Asian (2.6%), Other (1.3%), Hispanic/Latino (5.3%). Statistically significant improvements were observed in several domains between pre/post responses. Pts demonstrated increased understanding of placebo use in clinical trials (P = 0.0003), randomization (P = 0.0002),…
Read the paper
Related studies
- A Survey on Knowledge Graphs: Representation, Acquisition, and Applications
- Toxicity of nanomaterials
- The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies
- Halogen bonding (X‐bonding): A biological perspective
- Biofilm formation at the air–liquid interface by the Pseudomonas fluorescens SBW25 wrinkly spreader requires an acetylated form of cellulose
- Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.